LC-MS/MS method applied to preclinical pharmacokinetic investigation of olanzapine-loaded lipid-core nanocapsules

AUTOR(ES)

Dimer, Frantiescoli A., Pigatto, Maiara C., Pohlmann, Adriana R., Costa, Teresa Dalla, Guterres, Silvia S.

FONTE

Quím. Nova

DATA DE PUBLICAÇÃO

2014

RESUMO

In spite of different methods reported in the literature to determine olanzapine in biological fluids, all of them used high volumes of plasma. Therefore, the purpose of this paper was to develop an LC-MS/MS method using small plasma volume (0.1 mL) to apply in a preclinical pharmacokinetic investigation. The method was linear over the concentration ranges of 10 - 1000 ng mL-1. Extraction recoveries, stability, and validation parameters were evaluated. Results were within the acceptable limits of international guidelines. A significant decrease in clearance led to a significant 2.26-times increase in AUC0 - 6h of olanzapine-loaded lipid-core nanocapsules compared with free-olanzapine.

Documentos Relacionados

• CHARACTERIZING THE MECHANISM OF QUETIAPINE DISTRIBUTION IN LIPID-CORE NANOCAPSULES PSEUDO-PHASES USING A VALIDATED LC/UV METHOD
• Automated diagnosis of LC-MS/MS performance
• Investigations of the effect of the lipid matrix on drug entrapment, in vitro release, and physical stability of olanzapine-loaded solid lipid nanoparticles
• Quantitative approach to glucocorticosteroids analysis in human urine using LC-MS/MS
• Simultaneous Quantification of Plasma Catecholamines and Metanephrines by LC-MS/MS